We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-2.21%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$170M
AUM Growth
-$21.4M
Cap. Flow
-$8.68M
Cap. Flow %
-5.12%
Top 10 Hldgs %
56.85%
Holding
56
New
12
Increased
10
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$4.91M
2
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.73M
3
CLSD
Clearside Biomedical
CLSD
+$4.52M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.36M
5
BPMC
Blueprint Medicines
BPMC
+$2.86M

Top Sells

Rank Stock Value
1
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$5.03M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.99M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.61M
4
IMMU
Immunomedics Inc
IMMU
+$3.9M
5
ZGNX
Zogenix, Inc.
ZGNX
+$2.52M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
2 Miscellaneous 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$24.7M 14.54%
880,000
+95,000
+12% +$2.86M
AXGN icon
2
Axogen
AXGN
$2.78B
$17.7M 10.45%
1,970,000
-30,000
-2% -$258K
ARIA
3
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$12.4M 7.33%
1,000,000
-45,000
-4% -$542K
GNMX
4
DELISTED
Aevi Genomic Medicine Inc
GNMX
$7.77M 4.58%
1,500,000
-300,000
-17% -$1.58M
KYNB
5
Kyntra Bio
KYNB
$32.4M
$7.06M 4.16%
13,200
– –
FOMX
6
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.5M 3.24%
495,000
-135,000
-21% -$1.27M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.05B
$5.42M 3.2%
130,000
– –
CDXS icon
8
Codexis
CDXS
$182M
$5.38M 3.17%
1,170,000
– –
CMRX
9
DELISTED
Chimerix, Inc.
CMRX
$5.38M 3.17%
1,170,000
+390,000
+50% +$1.84M
NGNE icon
10
Neurogene
NGNE
$758M
$5.12M 3.02%
15,500
– –
TBPH icon
11
Theravance Biopharma
TBPH
$885M
$5.04M 2.97%
+158,200
New +$4.91M
MNTA
12
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.97M 2.93%
+330,000
New +$4.36M
ADMS
13
DELISTED
Adamas Pharmaceuticals
ADMS
$4.82M 2.84%
285,000
+35,000
+14% +$541K
TVRD
14
Tvardi Therapeutics
TVRD
$24M
$4.41M 2.6%
13,194
-5,556
-30% -$1.78M
PRTA icon
15
Prothena Corp
PRTA
$467M
$4.06M 2.39%
82,500
+32,500
+65% +$1.79M
LOXO
16
DELISTED
Loxo Oncology, Inc
LOXO
$4.01M 2.37%
125,000
+15,000
+14% +$384K
EGRX
17
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$3.97M 2.34%
50,000
-20,000
-29% -$1.45M
PDSB icon
18
PDS Biotechnology
PDSB
$12.2M
$3.5M 2.06%
14,000
– –
MGNX icon
19
MacroGenics
MGNX
$260M
$3.48M 2.05%
170,000
+25,000
+17% +$629K
XENE icon
20
Xenon Pharmaceuticals
XENE
$6B
$3.12M 1.84%
405,000
-5,000
-1% -$40.2K
ENTA icon
21
Enanta Pharmaceuticals
ENTA
$402M
$3.02M 1.78%
+90,000
New +$2.58M
SBBP
22
DELISTED
Strongbridge Biopharma plc.
SBBP
$2.78M 1.64%
+1,160,000
New +$4.73M
OMER icon
23
Omeros
OMER
$1.39B
$2.63M 1.55%
+265,300
New +$2.71M
CLSD
24
DELISTED
Clearside Biomedical
CLSD
$2.41M 1.42%
+18,000
New +$4.52M
IOVA icon
25
Iovance Biotherapeutics
IOVA
$3.74B
$2.08M 1.23%
300,000
+20,000
+7% +$138K
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2016 Portfolio in Review

As of Q4 2016, Opaleye Management held 56 positions worth $170M, down 11% from $191M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Opaleye Management withdrew a net $8.68M in Q4 2016, closing 16 positions and reducing 12 holdings. Its most notable exit was CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA), an estimated $5.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Theravance Biopharma worth $5.04M.

  • Opaleye Management's largest Q4 2016 buy was Theravance Biopharma: 158,200 shares worth $5.04M.
  • Opaleye Management added most to Blueprint Medicines in Q4 2016, an estimated $2.86M increase.
  • Opaleye Management's biggest Q4 2016 reduction was Tvardi Therapeutics, cutting an estimated $1.78M.
  • Opaleye Management fully exited CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) in Q4 2016, selling an estimated $5.03M.
  • Opaleye Management's ten largest holdings make up 57% of its $170M portfolio in Q4 2016.
  • Opaleye Management opened 12 new positions and closed 16 in Q4 2016.
  • Opaleye Management's portfolio value fell 11% quarter-over-quarter to $170M.

Based on Opaleye Management's 13F filing for Q4 2016, filed 21 Feb 2017.